EP2300004A4 - COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS - Google Patents

COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS

Info

Publication number
EP2300004A4
EP2300004A4 EP09747702A EP09747702A EP2300004A4 EP 2300004 A4 EP2300004 A4 EP 2300004A4 EP 09747702 A EP09747702 A EP 09747702A EP 09747702 A EP09747702 A EP 09747702A EP 2300004 A4 EP2300004 A4 EP 2300004A4
Authority
EP
European Patent Office
Prior art keywords
compositions
active compounds
transcription factor
thermal shock
methods relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09747702A
Other languages
German (de)
French (fr)
Other versions
EP2300004A2 (en
Inventor
Dennis J Thiele
Daniel W Neef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP2300004A2 publication Critical patent/EP2300004A2/en
Publication of EP2300004A4 publication Critical patent/EP2300004A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP09747702A 2008-05-15 2009-05-15 COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS Withdrawn EP2300004A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5351308P 2008-05-15 2008-05-15
PCT/US2009/044186 WO2009140621A2 (en) 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof

Publications (2)

Publication Number Publication Date
EP2300004A2 EP2300004A2 (en) 2011-03-30
EP2300004A4 true EP2300004A4 (en) 2012-05-30

Family

ID=41319361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09747702A Withdrawn EP2300004A4 (en) 2008-05-15 2009-05-15 COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS

Country Status (4)

Country Link
EP (1) EP2300004A4 (en)
CN (1) CN102088973A (en)
CA (1) CA2724413C (en)
WO (1) WO2009140621A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
KR101609856B1 (en) * 2010-03-17 2016-04-07 타이벡스 세라피틱스 코포레이션 Modulators of hec1 activity and methods therefor
CN102918034B (en) 2010-03-30 2015-06-03 维颂公司 Polysubstituted aromatic compounds as inhibitors of thrombin
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
ES2736999T3 (en) 2011-11-21 2020-01-09 Taivex Therapeutics Corp Biomarkers for cancers that respond to modulators of Hec1 activity
LT2968297T (en) 2013-03-15 2019-01-10 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
ES2791749T3 (en) 2013-03-15 2020-11-05 Verseon Corp Halogenopyrazoles as thrombin inhibitors
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CN106687445A (en) 2014-09-17 2017-05-17 维颂公司 Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
RU2017131562A (en) 2015-02-27 2019-03-27 Версеон Корпорейшн SUBSTITUTED PYRAZOLIC COMPOUNDS AS SERINE PROTEASES INHIBITORS
WO2017019772A1 (en) * 2015-07-27 2017-02-02 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
CN105524056A (en) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 Aminothiazole compound, and preparation method and application thereof
CN107519239A (en) * 2017-04-25 2017-12-29 兰州大学 Baical Skullcap root P.E is preparing the application in activating HSP70 medicines
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
JP7189368B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
FI3873884T3 (en) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE-2,4-DIONE DERIVATIVES AS ALPHA-4-BETA-7 INTEGRIN INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES
IL284589B2 (en) 2019-01-31 2025-10-01 Pfizer 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN113087783B (en) * 2021-04-20 2021-10-01 南京医科大学 Small Molecular Polypeptides in HD Therapeutic Drugs and Their Applications
JP2025507542A (en) * 2022-02-23 2025-03-21 バイオヘイブン・セラピューティクス・リミテッド PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATERS
CN120754089A (en) * 2025-08-14 2025-10-10 复旦大学附属肿瘤医院 Application of HSF1A in preparation of anti-lung cancer metastasis drugs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005026137A2 (en) * 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2005041879A2 (en) * 2003-10-28 2005-05-12 Pharmacia Corporation COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2006013054A1 (en) * 2004-08-05 2006-02-09 F. Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005026137A2 (en) * 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2005041879A2 (en) * 2003-10-28 2005-05-12 Pharmacia Corporation COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2006013054A1 (en) * 2004-08-05 2006-02-09 F. Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BATULAN Z ET AL: "Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 24, no. 2, 1 November 2006 (2006-11-01), pages 213 - 225, XP024901478, ISSN: 0969-9961, [retrieved on 20061101], DOI: 10.1016/J.NBD.2006.06.017 *
BORGHINI A ET AL: "QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 18, 15 September 2005 (2005-09-15), pages 5330 - 5337, XP027637888, ISSN: 0968-0896, [retrieved on 20050915] *
DANIEL W. NEEF ET AL: "Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases", NATURE REVIEWS DRUG DISCOVERY, vol. 10, no. 12, 1 January 2011 (2011-01-01), pages 930 - 944, XP055024215, ISSN: 1474-1776, DOI: 10.1038/nrd3453 *
GALAM ET AL: "High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 5, 31 January 2007 (2007-01-31), pages 1939 - 1946, XP005867161, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2007.01.004 *
GOBLYOS A ET AL: "Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 6, 15 March 2005 (2005-03-15), pages 2079 - 2087, XP027637658, ISSN: 0968-0896, [retrieved on 20050315] *
LEONE S ET AL: "SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 16, no. 10, 30 March 2008 (2008-03-30), pages 5695 - 5703, XP022673151, ISSN: 0968-0896, [retrieved on 20080330], DOI: 10.1016/J.BMC.2008.03.067 *
NEEF DANIEL W ET AL: "Modulation of Heat Shock Transcription Factor 1 as a Therapeutic Target for Small Molecule Intervention in Neurodegenerative Disease", PLOS BIOLOGY, vol. 8, no. 1, January 2010 (2010-01-01), XP002673717 *
POWERS ET AL: "Inhibitors of the heat shock response: Biology and pharmacology", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 19, 31 July 2007 (2007-07-31), pages 3758 - 3769, XP022191504, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2007.05.040 *
SALEHI A H ET AL: "AEG3482 Is an Antiapoptotic Compound that Inhibits Jun Kinase Activity and Cell Death through Induced Expression of Heat Shock Protein 70", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 13, no. 2, 1 February 2006 (2006-02-01), pages 213 - 223, XP025131819, ISSN: 1074-5521, [retrieved on 20060201], DOI: 10.1016/J.CHEMBIOL.2005.11.012 *
TROTT AMY ET AL: "Activation of heat shock and antioxidant responses by the natural product celastrol: Transcriptional signatures of a thiol-targeted molecule", MOLECULAR BIOLOGY OF THE CELL, vol. 19, no. 3, March 2008 (2008-03-01), pages 1104 - 1112, XP002673716, ISSN: 1059-1524 *
WESTERHEIDE SANDY D ET AL: "Heat shock response modulators as therapeutic tools for diseases of protein conformation", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 280, no. 39, 1 September 2005 (2005-09-01), pages 33097 - 33100, XP002637231, ISSN: 0021-9258, DOI: 10.1074/JBC.R500010200 *

Also Published As

Publication number Publication date
WO2009140621A8 (en) 2011-05-12
WO2009140621A3 (en) 2010-02-25
CN102088973A (en) 2011-06-08
EP2300004A2 (en) 2011-03-30
CA2724413C (en) 2016-10-18
CA2724413A1 (en) 2009-11-19
WO2009140621A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
EP2300004A4 (en) COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS
EP2637658A4 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH THERMAL SHOCK TRANSCRIPTION FACTOR ACTIVATOR COMPOUNDS AND TARGETS THEREOF
BRPI0912046A2 (en) hybridization compositions and methods
IL210153A0 (en) Nutrigenomics methods and compositions
EP2217250A4 (en) IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
BRPI0913127A2 (en) cooling composition
EP2139331A4 (en) COMPOSITIONS AND METHODS RELATING TO NEW COMPOUNDS AND TARGETS THEREOF
PL2356462T3 (en) Anti-CXCR1 compositions and methods
EP2296475A4 (en) TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
EP2503995A4 (en) METHODS, COMPOSITIONS AND LYOPHILIZATION KITS
EP2365978A4 (en) COMPOSITIONS OF LECITHIN AND PLASTIFIANT AND METHODS
GB0815872D0 (en) Novel method and compositions
IL210559A0 (en) Novel compositions and methods
GB0819530D0 (en) Methods and compositions
DE112009000197T8 (en) Schier composition
IL210588A0 (en) Novel compositions and methods
GB0817585D0 (en) Novel compositions and methods
EP2370091A4 (en) COMPOSITIONS AND METHODS RELATED TO MIR-31
EP2473176A4 (en) NEUROPROTECTIVE COMPOUNDS, COMPOSITIONS, METHODS AND KITS
PL2262828T3 (en) Compositions, methods and kits
PT2320888E (en) Laidlomycin compositions and methods
GB0807760D0 (en) Fireplace
PL2192375T3 (en) Game target with background light
FI8103U1 (en) Fireplace / oven
SM200800030B (en) Equalization method for transmissions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 277/60 20060101ALI20120418BHEP

Ipc: A61K 31/4155 20060101ALI20120418BHEP

Ipc: A61K 31/415 20060101AFI20120418BHEP

Ipc: A61K 31/426 20060101ALI20120418BHEP

Ipc: A61K 45/06 20060101ALI20120418BHEP

Ipc: A61P 25/28 20060101ALI20120418BHEP

Ipc: C07D 277/38 20060101ALI20120418BHEP

Ipc: A61P 25/16 20060101ALI20120418BHEP

Ipc: A61P 35/00 20060101ALI20120418BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120502

17Q First examination report despatched

Effective date: 20131205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180213